XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.25.3

REVENUES | 9 Months Ended
--- | ---
Sep. 30, 2025
Revenue from Contract with Customer [Abstract] |
REVENUES | REVENUES Disaggregation of Revenues The following table summarizes our Total revenues:
|  | Three Months Ended September 30, 2025 |  | Three Months Ended September 30, 2024
(in millions) |  | U.S. |  | Europe |  | Rest of World |  | Total |  | U.S. |  | Europe |  | Rest of World |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 2,940 |  |  | $ | 427 |  |  | $ | 320 |  |  | $ | 3,686 |  |  | $ | 2,826 |  |  | $ | 375 |  |  | $ | 272 |  |  | $ | 3,472 |
Descovy |  | 652 |  |  | 23 |  |  | 25 |  |  | 701 |  |  | 534 |  |  | 24 |  |  | 28 |  |  | 586 |
Genvoya |  | 323 |  |  | 34 |  |  | 19 |  |  | 377 |  |  | 384 |  |  | 44 |  |  | 21 |  |  | 449 |
Odefsey |  | 206 |  |  | 61 |  |  | 10 |  |  | 277 |  |  | 248 |  |  | 69 |  |  | 9 |  |  | 326 |
Symtuza - Revenue share(1) |  | 95 |  |  | 26 |  |  | 3 |  |  | 124 |  |  | 103 |  |  | 33 |  |  | 3 |  |  | 139 |
Other HIV(2) |  | 82 |  |  | 22 |  |  | 9 |  |  | 112 |  |  | 65 |  |  | 26 |  |  | 9 |  |  | 100 |
Total HIV |  | 4,299 |  |  | 592 |  |  | 386 |  |  | 5,277 |  |  | 4,161 |  |  | 570 |  |  | 342 |  |  | 5,073 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sofosbuvir/Velpatasvir(3) |  | 146 |  |  | 65 |  |  | 97 |  |  | 309 |  |  | 222 |  |  | 67 |  |  | 96 |  |  | 385 |
Vemlidy |  | 136 |  |  | 12 |  |  | 132 |  |  | 280 |  |  | 126 |  |  | 11 |  |  | 95 |  |  | 232 |
Other Liver Disease(4) |  | 132 |  |  | 81 |  |  | 17 |  |  | 231 |  |  | 45 |  |  | 54 |  |  | 17 |  |  | 116 |
Total Liver Disease |  | 414 |  |  | 158 |  |  | 247 |  |  | 819 |  |  | 393 |  |  | 132 |  |  | 207 |  |  | 733 |
Veklury |  | 140 |  |  | 43 |  |  | 93 |  |  | 277 |  |  | 393 |  |  | 81 |  |  | 219 |  |  | 692 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 40 |  |  | 35 |  |  | 8 |  |  | 83 |  |  | 63 |  |  | 29 |  |  | 6 |  |  | 98 |
Yescarta |  | 123 |  |  | 151 |  |  | 75 |  |  | 349 |  |  | 145 |  |  | 182 |  |  | 60 |  |  | 387 |
Total Cell Therapy |  | 163 |  |  | 186 |  |  | 83 |  |  | 432 |  |  | 208 |  |  | 211 |  |  | 66 |  |  | 485 |
Trodelvy |  | 221 |  |  | 89 |  |  | 47 |  |  | 357 |  |  | 226 |  |  | 80 |  |  | 26 |  |  | 332 |
Total Oncology |  | 384 |  |  | 275 |  |  | 129 |  |  | 788 |  |  | 433 |  |  | 291 |  |  | 92 |  |  | 816 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 2 |  |  | 69 |  |  | 52 |  |  | 123 |  |  | 6 |  |  | 71 |  |  | 52 |  |  | 130 |
Other(5) |  | 34 |  |  | 7 |  |  | 20 |  |  | 61 |  |  | 47 |  |  | 8 |  |  | 16 |  |  | 71 |
Total Other |  | 36 |  |  | 76 |  |  | 72 |  |  | 184 |  |  | 53 |  |  | 80 |  |  | 68 |  |  | 201 |
Total product sales |  | 5,274 |  |  | 1,144 |  |  | 928 |  |  | 7,345 |  |  | 5,433 |  |  | 1,154 |  |  | 928 |  |  | 7,515 |
Royalty, contract and other revenues |  | 7 |  |  | 411 |  |  | 5 |  |  | 424 |  |  | 17 |  |  | 13 |  |  | 1 |  |  | 30 |
Total revenues |  | $ | 5,281 |  |  | $ | 1,555 |  |  | $ | 933 |  |  | $ | 7,769 |  |  | $ | 5,450 |  |  | $ | 1,167 |  |  | $ | 929 |  |  | $ | 7,545 |
|  | Nine Months Ended September 30, 2025 |  | Nine Months Ended September 30, 2024
(in millions) |  | U.S. |  | Europe |  | Rest of World |  | Total |  | U.S. |  | Europe |  | Rest of World |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
HIV |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biktarvy |  | $ | 8,212 |  |  | $ | 1,231 |  |  | $ | 922 |  |  | $ | 10,366 |  |  | $ | 7,726 |  |  | $ | 1,110 |  |  | $ | 814 |  |  | $ | 9,649 |
Descovy |  | 1,791 |  |  | 67 |  |  | 81 |  |  | 1,939 |  |  | 1,339 |  |  | 75 |  |  | 82 |  |  | 1,496 |
Genvoya |  | 950 |  |  | 114 |  |  | 54 |  |  | 1,118 |  |  | 1,088 |  |  | 138 |  |  | 66 |  |  | 1,292 |
Odefsey |  | 642 |  |  | 184 |  |  | 30 |  |  | 857 |  |  | 705 |  |  | 217 |  |  | 30 |  |  | 952 |
Symtuza - Revenue share(1) |  | 265 |  |  | 88 |  |  | 9 |  |  | 362 |  |  | 338 |  |  | 101 |  |  | 9 |  |  | 448 |
Other HIV(2) |  | 198 |  |  | 85 |  |  | 28 |  |  | 310 |  |  | 190 |  |  | 96 |  |  | 36 |  |  | 322 |
Total HIV |  | 12,059 |  |  | 1,769 |  |  | 1,124 |  |  | 14,952 |  |  | 11,386 |  |  | 1,737 |  |  | 1,038 |  |  | 14,160 |
Liver Disease |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sofosbuvir/Velpatasvir(3) |  | 497 |  |  | 227 |  |  | 273 |  |  | 996 |  |  | 737 |  |  | 230 |  |  | 299 |  |  | 1,266 |
Vemlidy |  | 358 |  |  | 36 |  |  | 389 |  |  | 783 |  |  | 338 |  |  | 33 |  |  | 328 |  |  | 699 |
Other Liver Disease(4) |  | 307 |  |  | 233 |  |  | 53 |  |  | 593 |  |  | 134 |  |  | 148 |  |  | 55 |  |  | 337 |
Total Liver Disease |  | 1,162 |  |  | 496 |  |  | 714 |  |  | 2,372 |  |  | 1,210 |  |  | 411 |  |  | 682 |  |  | 2,302 |
Veklury |  | 390 |  |  | 84 |  |  | 225 |  |  | 700 |  |  | 784 |  |  | 204 |  |  | 473 |  |  | 1,461 |
Oncology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cell Therapy |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tecartus |  | 122 |  |  | 107 |  |  | 25 |  |  | 254 |  |  | 181 |  |  | 102 |  |  | 22 |  |  | 305 |
Yescarta |  | 444 |  |  | 455 |  |  | 228 |  |  | 1,127 |  |  | 502 |  |  | 509 |  |  | 170 |  |  | 1,181 |
Total Cell Therapy |  | 566 |  |  | 562 |  |  | 253 |  |  | 1,381 |  |  | 683 |  |  | 611 |  |  | 192 |  |  | 1,485 |
Trodelvy |  | 626 |  |  | 259 |  |  | 128 |  |  | 1,013 |  |  | 655 |  |  | 217 |  |  | 88 |  |  | 960 |
Total Oncology |  | 1,192 |  |  | 821 |  |  | 381 |  |  | 2,395 |  |  | 1,338 |  |  | 828 |  |  | 280 |  |  | 2,446 |
Other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AmBisome |  | 15 |  |  | 201 |  |  | 175 |  |  | 391 |  |  | 37 |  |  | 210 |  |  | 176 |  |  | 424 |
Other(5) |  | 125 |  |  | 23 |  |  | 55 |  |  | 204 |  |  | 203 |  |  | 26 |  |  | 52 |  |  | 281 |
Total Other |  | 140 |  |  | 225 |  |  | 230 |  |  | 594 |  |  | 241 |  |  | 236 |  |  | 228 |  |  | 705 |
Total product sales |  | 14,943 |  |  | 3,395 |  |  | 2,674 |  |  | 21,013 |  |  | 14,958 |  |  | 3,416 |  |  | 2,700 |  |  | 21,074 |
Royalty, contract and other revenues |  | 57 |  |  | 433 |  |  | 16 |  |  | 505 |  |  | 66 |  |  | 43 |  |  | 2 |  |  | 111 |
Total revenues |  | $ | 15,000 |  |  | $ | 3,828 |  |  | $ | 2,690 |  |  | $ | 21,518 |  |  | $ | 15,024 |  |  | $ | 3,459 |  |  | $ | 2,703 |  |  | $ | 21,185 |
_______________________________ (1) Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen Ireland”). (2) Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada, Tybost and Yeztugo/Yeytuo. (3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”). (4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi. (5) Includes Cayston, Jyseleca, Letairis and Zydelig. Revenues Recognized from Performance Obligations Satisfied in Prior Years The following table summarizes revenues recognized from performance obligations satisfied in prior years:
|  | Three Months Ended |  | Nine Months Ended
|  | September 30, |  | September 30,
(in millions) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Revenue share with Janssen Ireland and royalties for licenses of intellectual property |  | $ | 148 |  |  | $ | 173 |  |  | $ | 458 |  |  | $ | 545 |
Changes in estimates(1) |  | $ | 497 |  |  | $ | 146 |  |  | $ | 837 |  |  | $ | 388 |
_______________________________ (1) Changes in estimates increased during the three and nine months ended September 30, 2025 primarily due to recognition of $400 million of previously constrained revenues from the sale of certain intellectual property. Contract Balances The following table summarizes our contract balances:
(in millions) |  | September 30, 2025 |  | December 31, 2024
Contract assets(1) |  | $ | 695 |  |  | $ | 277 |
Contract liabilities(2) |  | $ | 56 |  |  | $ | 58 |
_______________________________ (1) The increase in contract assets during the nine months ended September 30, 2025 primarily related to recognition of $400 million of previously constrained revenues from the sale of certain intellectual property. (2) Future revenues recognized from contract liabilities are not expected to be material in any one year.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration